Table 1.
Baseline characteristics of colon cancer patients stratified based on EEF1A1 expression.
| EEF1A1-Low (n = 42) | EEF1A1-High (n = 239) | p-Value | |
|---|---|---|---|
| Age (years) | |||
| <65 | 22 (52.4%) | 113 (47.3%) | 0.616 |
| ≥65 | 20 (47.6%) | 126 (52.7%) | |
| Sex | |||
| Male | 26 (61.9%) | 129 (54.0%) | 0.402 |
| Female | 16 (38.1%) | 110 (46.0%) | |
| Body mass index (BMI) (kg/m2) | |||
| <18.5 | 2 (4.8%) | 17 (7.1%) | 0.839 |
| 18.5–25.0 | 23 (54.7%) | 124 (51.9%) | |
| >25.0 | 17 (40.5%) | 98 (41.0%) | |
| Number of comorbid diseases | |||
| 0 | 23 (54.8%) | 101 (42.3%) | 0.265 |
| 1 | 10 (23.8%) | 84 (35.1%) | |
| ≥2 | 9 (21.4%) | 54 (22.6%) | |
| Location of primary cancer | |||
| Left | 20 (47.6%) | 152 (63.6%) | 0.059 |
| Right | 22 (52.4%) | 87 (36.4%) | 0.059 |
| Pre-operative carcinoembryonic antigen (CEA) | |||
| <5 ng/mL | 27 (64.3%) | 151 (63.4%) | 1.000 |
| >5 ng/mL | 15 (35.7%) | 87 (36.6%) | |
| Bowel obstruction or perforation | |||
| No | 32 (76.2%) | 215 (90.0%) | 0.019 |
| Yes | 10 (23.8%) | 24 (10.0%) | |
| Adjuvant chemotherapy | |||
| No | 11 (76.2%) | 50 (20.9%) | 0.424 |
| Yes | 31 (73.8%) | 189 (79.1%) | |
| Stage (tumor/node/metastasis, TNM) | |||
| II | 15 (35.7%) | 117 (49.0%) | 0.132 |
| III | 27 (64.3%) | 122 (51.0%) | |
| pT stage | |||
| 2 | 1 (2.4%) | 10 (4.2%) | 0.097 |
| 3 | 30 (71.4%) | 197 (82.4%) | |
| 4 | 11 (26.2%) | 32 (13.4%) | |
| pN stage | 0.076 | ||
| 0 | 15 (35.7%) | 118 (49.4%) | |
| 1 | 18 (42.9%) | 62 (25.9%) | |
| 2 | 9 (21.4%) | 59 (24.7%) | |
| Differentiation | 0.319 | ||
| Well | 1 (2.4%) | 6 (2.5%) | |
| Moderate | 36 (87.8%) | 223 (93.3%) | |
| Poor | 4 (9.8%) | 10 (4.2%) | |
| Perineural invasion | 0.083 | ||
| No | 21 (50.0%) | 155 (64.9%) | |
| Yes | 21 (50.0%) | 84 (35.1%) | |
| Venous invasion | 0.503 | ||
| No | 37 (88.1%) | 199 (83.3%) | |
| Yes | 5 (11.9%) | 40 (16.7%) | |
| Lymphatic invasion | 0.610 | ||
| No | 27 (64.3%) | 141 (59.0%) | |
| Yes | 15 (35.7%) | 98 (41.0%) | |
| Number of harvested lymoh nodes | 23.5 (10–63) | 22 (4–115) | 0.259 |
| Number of metastatic lymph nodes | 1 (0–15) | 1 (0–18) | 0.560 |
| Metastatic lymphnodes/harvested lymph nodesratio | 4.9 (0–66.7) | 2.6 (0–100) | 0.943 |
| KRAS 1 | 0.811 | ||
| Wild-type | 14 (66.7%) | 77 (63.1%) | |
| Mutant | 7 (33.3%) | 45 (36.9%) |
1KRAS; V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog gene.